This Web Site is committed to the memory of Janis Morrow.
What's New At Janis And Friends ?
2009
July
FDA panel backs cut in maximum Tylenol dosage
June
May 30 - June 4, 2009, Chicago, Illinois
May
HCV Advocate Newsletter:
May 2009
April
From HCV Advocate:
HCV Advocate Newsletter April, 2009
SVR – 5 Years Later
Alan Franciscus, Editor-in-Chief
March
13th International Symposium on Viral Hepatitis and Liver Disease
March 20-24, 2009
Washington, DC
Also See:
HIV and
Hepatitis.com Coverage of the
13th International Symposium on Viral
Hepatitis and Liver Disease (ISVHLD 2009)
March 20 - 24, 2009, Washington, DC
For up to date Hepatitis related news, blog and clinical trial listings
HCV Advocate Newsletter March, 2009
Stimulus Help with COBRA Premiums
HCV Advocate Newsletter
February 2009
Read the hepc.bull -
online monthly newsletter
HCV Advocate
Newsletter:
January, 2009
Free Hepatitis C Online Book Updated:
Hepatitis C Choices, 4th Edition
Table of Contents
Individual chapters are available below in PDF format, or you can download the complete book here (9.23MB)
PART 1: Information for Everyone with Hepatitis C
1: How to Use Hepatitis C Choices
(4 pages, 436 KB)2: Overview of Hepatitis C (8 pages, 470 KB)
Robert G. Gish, MD3: Alcohol and Hepatitis C (10 pages, 639 KB)
Douglas R. LaBrecque, MD and Lorren Sandt4: Understanding Hepatitis C Disease
Section 1: Liver Disease Progression
(11 pages, 978 KB)
Lorren SandtSection 2: Promoting Liver Health
(8 pages, 413 KB)
Lorren Sandt5: Signs and Symptoms That May Be Associated with Hepatitis C (8 pages, 385 KB)
Tina M. St. John, MD6: Laboratory Tests and Procedures
(20 pages, 1.17MB)
Tina M. St. John, MD7: The Immune System and Hepatitis C
Section 1: Meet the Immune System
(10 pages, 580 KB)
Tina M. St. John, MDSection 2: Immunology Takes on Hepatitis C (19 pages, 1.97 MB)
Stewart Cooper, MD
PART 2: Hepatitis C Treatment and Management Approaches
8: Western (Allopathic) Medicine
Section 1: Allopathic Hepatitis C Treatment Overview
(5 pages, 377 KB)
Douglas R. LaBrecque, MDSection 2: Initial Treatment Options
(15 pages, 538 KB)
Douglas R. LaBrecque, MDSection 3: Options When Initial Treatment Fails to Clear the Hepatitis C Virus
(10 pages, 536 KB)
Gregory T. Everson, MDSection 4: Future of Allopathic Hepatitis C Treatment
(12 pages, 515 KB)
Robert G. Gish, MD9: Integrative Medicine (7 pages, 429 KB)
Randy J. Horwitz, MD, PhD and Julia Jernberg, MD10: Ayurvedic Medicine (13 pages, 535 KB)
Shri K. Mishra, MD, MS, Bharathi Ravi, BAMS, and Sivaramaprasad Vinjamury, MD11: Chinese Medicine
Section 1: Traditional Chinese Medicine and Hepatitis C (8 pages, 401 KB)
Misha Cohen, OMD, LAcSection 2: Modern Chinese Medicine Therapeutics for Hepatitis C (14 pages, 473 KB)
Qing Cai Zhang, MD (China), LAc12: Homeopathic Medicine (8 pages, 424 KB)
Sylvia Flesner, ND13: Mind-Body Medicine & Spiritual Healing
(12 pages, 481 KB)
Sharon D. Montes, MD14: Naturopathic Medicine (14 pages, 509 KB)
J. Lyn Patrick, ND15: Nutrition and Hepatitis C (12 pages, 431 KB)
Lark Lands, PhD16: Nutritional Supplementation (9 pages, 394 KB)
Lark Lands, PhD and J. Lyn Patrick, ND17: Products Marketed to People with Hepatitis C
(12 pages, 467 KB)
J. Lyn Patrick, NDPART 3: Other Topics for People Living with Hepatitis C
18: Women and Hepatitis C (12 pages, 1.49 MB)
Norah Terrault, MD and Jessica Irwin, PAC19: Hepatitis C in Children (6 pages, 431 KB)
Aparna Roy, MD, MPH and Kathleen Schwarz, MD20: HIV/HCV Coinfection
Section 1: Overview of HIV/HCV Coinfection (10 pages, 694 KB)
Misha Cohen, OMD, LAc and Tina M. St. John, MDSection 2: Western (Allopathic) Treatment Options (14 pages, 577 KB)
Tina M. St. John, MD and Misha Cohen, OMD, LAcSection 3: Alternative Eastern Treatment Options (6 pages, 360 KB)
Misha Cohen, OMD, LAcSection 4: Naturopathic Treatment Options
(6 pages, 376 KB)
J. Lyn Patrick, ND21: Mental Health & Hepatitis C
Section 1: Mental Health & Neurocognitive Issues Associated with Hepatitis C Infection
(8 pages, 476 KB)
Julie Nelligan, PhD, David W. Indest, PsyD, and Peter Hauser, MDSection 2: Mental Health Issues in the Setting of Interferon-Based Therapy
(16 pages, 549 KB)
Joyce Seiko Kobayashi, MDSection 3: Interferon-Based Therapy in Recovery (6 pages, 410 KB)
Amy E. Smith, PAC and Diana L. Sylvestre, MDSection 4: Psychosocial Issues and HCV
(8 pages, 435 KB)
Susan L. Zickmund, PhD22: Military Veterans & Hepatitis C
(8 pages, 463 KB)
Terry Baker23: Choosing: My Journey, My Choices
(16 pages, 614 KB)
Randy Dietrich24: A Look to the Future (8 pages, 434 KB)
Lorren Sandt
APPENDICES
I: How to Cut Down on Your Drinking
(4 pages, 357 KB)II: Ayurvedic Herbs (8 pages, 380 KB)
III: Chinese Medicine Herbs and Formulas
(10 pages, 441 KB)IV: Liver-Toxic Medications and Herbs
(4 pages, 366 KB)
Sept
Denise Treating With Protease Inhibitor Telaprevir Vertex-950
Read more on our message boards
I can't believe I only have 3 days of Riba left! It was so great to fill up my pill dispenser for the week and be able to leave some days empty!!!
It's been a rough ride(who's treatment isn't?!?) but if I can hold onto that UD it will all have been worth it.
Iam1a, Stage2, Grade 1-2. I was in a 48 week arm. The first 24 weeks I took the standard treatment as well as the Telaprevir. The last 24 weeks have been standard treatment only.
They did not allow rescue drugs in the Prove 3 trial and I became anemic real quick...just like the last time I treated. Since Procrit wasn't an option they had to dose reduce/discontinue my Riba for most of the trial. I was only on full dose Riba for a few of the 48 weeks. It's been shown that Riba is a necessary part of the cocktail so I was VERY nervous. I wasn't able to get any VL results until my 24 week results. At that time I found out that I went from 12,500,000 on my start date to <30 by week 4! The first time I treated with SOC I didn't have a 2 log drop by week 13 and stopped. At that time I started with a much lower VL of 2,380,000. That just give's you an idea of how powerful these PI's are.
Vertex is continuing trails with the Telaprevir as well as 2 other PI's.
Vertex has submitted some late extracts regarding Prove 3 preliminary results to be presented at the EASL meeting in April. I have a feeling it's going to be more great news from Vertex.
I learned everythingI needed to get me through the past 48 weeks right here on J&F and will always be grateful for this site and the people here.
I owe Karen a huge debt of gratitude. She has been there for me every day and when I didn't feel like talking to ANYONE, Karen was the exception. Thank you my friend. Now, we need to get you on a PI so we can start planning that trip!
A friend of mine has declared Thursday as "All bad things gone and only good things to come,day!";-)
Thanks again to everyone for the well wishes and hope to start posting again as my system starts to clear.
If anyone has any questions about the Prove 3 trail feel free to email me through my profile.
BTW, I LOVE VERTEX!!!
Denise...next stop SVR...
UPDATE April 30th 08
|
April
Janis and Friends Forum: Read and Comment on EASL Coverage.
Advocate EASL 2008 Coverage
April 24
HIV and Hepatitis.com
Coverage of the
43rd
EASL Conference
(EASL 2008)
April 23 - 27, 2008,
Milan Italy
March 2008
We are pleased to announce Donna Fanelli MSN NP has joined us in
answering your questions about HCV and treatment.
Click below to Ask Donna your HCV questions
You will need to Join our forum with a quick registration
Donna J. C. Fanelli, MSN, NP-C, Medical Director of Primary Health and Wellness Center, LLC, in Milburn, NJ and Senior Clinical Research Coordinator of Gastroenterology Research Associates, LLC, in Cedar Knolls, NJ. She is certified as an Acute Care Nurse Practitioner, an Adult Nurse Practitioner, and a certified Sexual Assault Forensic Examiner.
We are very pleased to provide information in this forum. The information provided is for general educational purposes only and is intended to help users learn about health and diagnosed diseases. As always be sure to discuss matters with your doctor prior to making any important decisions regarding therapy choices. Your doctor knows you best.
April 2007
42nd EASL
April 11 - 15, 2007
Barcelona, Spain
THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
May 2006
May 20 - 25, 2006, Los Angeles, California
Guidelines for the Management of Hepatitis C Virus Infection
Coverage of the
41st Annual Meeting of the European Association for the Study of the Liver
April 26 - 30, 2006,
Vienna, Austria
Guidelines for the Management of Hepatitis C Virus Infection
June 2005
Read our members first hand experiences on the following HCV therapies: Infergen, Pegasys, and PegIntron
Join our messages boards and take part in the discussions
Click here to Join our Message Boards
From HIV and Hepatitis :
40th Annual meeting of the European Association for the Study of the Liver (40th EASL)
April 13 - 17, 2005, Paris, France
I would like to receive a free copy of Hepatitis Magazine .
How do I do that?
1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients
March 1-2, 2005, Paris, France
Researcher Cites “Potential Bias" Toward Peg Intron in New Trial
Jan 12 2005
AASLD 2004 Research Conferences
Oct 29- Nov 1 2004 Research Conferences
Our message boards have the latest reports coming out of the AASLD . Here you can also comment on the research.
From
Janis and Friends :AASLD 2004 & CONFERENCES DATA
HIVandHepatitis.com and HCVAdvocate.org are the best sites for the AASLD 2004 Research Conferences .
Clicking below will take you away from our site, click on your back button to return to Janis and Friends
From HIVandHepatitis.com :
55th Annual Meeting of the American
Society for the Study of Liver Diseases (55th AASLD)
October 29 - November 2, 2004, Boston, MA
From HCV Advocate :
Our Mission
We are committed to providing the best, up-to-date information regarding all aspects of Hepatitis C. Our goal is to help you and your loved ones become better equipped to handle this disease through knowledge and understanding.
There are approximately 400 million people infected with the Hepatitis C Virus worldwide. An estimated 75% to 85% are chronic and have symptoms. Hepatitis C is one of the most important causes of liver disease; and, sadly enough has become the most common reason for liver transplants in the United States. You may be one of the 5 million people in the United States who suffers from HCV.
An estimated 20% of those develop cirrhosis, liver cancer, or end-stage liver disease. Our Website has a collection of the latest medical news and clinical information on this disease including reports from recent conferences, news articles, Web searches, and links to other related sources on the Web
This information has been compiled from a variety of sources; mainly the CDC website
http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm
Disclaimer
Any information found on this site is for educational purposes only. We do not give out any medical advice. Janis and Friends does not endorse any Physicians or Pharmaceutical companies mentioned throughout our Web Site. We strongly recommend you see your HEALTHCARE PROFESSIONAL for the quality care you deserve. Please do not use any information found on our Web Site for diagnosing any aspect of your disease.
Funding
This site does not use any advertisements whatsoever. We are not funded by any outside contributions.
We subscribe to the HON code principles
Health On the Net Foundation Verify here